Behind the bench: Tips to simultaneously analyze THC, its metabolites, and other drugs of abuse using LC-MS

Significance of the topic

The routine inclusion of THC and its metabolites in multi-analyte LC-MS toxicology assays is increasingly important for forensic, clinical, workplace and impaired-driving testing. Cannabis is the second most commonly detected impairing drug after alcohol, and population-level use remains high. Combining THC testing with broader drug panels reduces cost, turnaround time and sample handling while providing timely, legally defensible results for matrices that reflect recent use (blood, oral fluid) and historical exposure (urine).

Objectives and study overview

This application-focused note outlines practical strategies and method optimizations to reliably extract, separate and detect THC, major metabolites (11-hydroxy-THC, THC-COOH and THC-COOH-glucuronide) and other drugs of abuse by LC-MS. Goals include maximizing recovery and signal, reducing nonspecific adsorption and matrix effects, ensuring chromatographic selectivity (including Δ8/Δ9 isomer separation) and establishing robust workflows for oral fluid, blood and urine testing within a larger drug panel.

Methodology

Key development principles and experiments described:

• Extraction optimization using dispersive SPE XTR tips with mixed-mode SCX/WAX chemistry to retain a broad panel of 31 drugs while improving THC recovery.
• Systematic evaluation of organic content during collection, extraction and reconstitution, including dry-down tests and sequential elution experiments to determine complete analyte recovery.
• Wash solvent screening (triplicate tests using 0%, 10%, 20%, 30% MeOH) to balance THC retention versus loss of more polar drugs (e.g., opioids).
• Recovery studies by spiking matrix pre- and post-extraction to calculate percent recovery and identify losses attributable to extraction or consumables.
• Chromatographic method tuning to resolve positional isomers (Δ8 vs Δ9 THC-COOH) using pentafluorophenyl (PFP) or fluoro-phenyl phases and optimized gradients.

Instrumentation used

The work references and tests with the following instrumentation and consumables (representative examples):

• UHPLC systems: Vanquish Horizon.
• Mass spectrometers: Stellar MS and Orbitrap Exploris 120 for high-resolution confirmation.
• Columns: Biphenyl reversed-phase (Accucore Biphenyl), Pentafluorophenyl / FluoroPhenyl (e.g., Raptor FluoroPhenyl 2.7 µm 100 x 2.1 mm) for isomer separation; alternatives to C18 recommended.
• Sample preparation: DPX XTR INTip dispersive SPE tips with mixed-mode SCX/WAX sorbent.
• Consumables: Silanized glass test tubes and silanized conical vial inserts to minimize adsorption; Quantisal oral fluid collection buffer for improved THC stability and signal.

Main results and discussion

Practical outcomes and observed effects:

• Organic content during collection and extraction is critical. Adding methanol (MeOH) early and maintaining MeOH throughout extraction mitigates nonspecific adsorption of lipophilic THC to plasticware and sorbents. For oral fluid, a final sample/internal-standard composition of ~20% MeOH and a SPE wash at 30% MeOH improved THC binding and recovery.
• Consumables matter: using silanized glass vials and inserts reduced THC loss relative to untreated plastic.
• Method optimizations delivered a roughly 7-fold increase in THC signal in extracted oral fluid by combining the following changes: increasing MeOH-diluted internal standard volume (from 10% to 20% of sample volume), raising SPE wash MeOH from 10% to 30%, switching from a C18 to biphenyl column, and adding the organic portion of reconstitution solvent before the aqueous portion.
• Recovery: the described oral fluid workflow achieved >70% recovery for THC while maintaining performance for the full 31-analyte panel and meeting required cutoffs.
• Buffer choice: Quantisal oral fluid buffer produced dramatically higher THC peak areas (reported ~150x increase) versus a common alternative buffer tested.
• Isomer separation: Δ8-THC-COOH and Δ9-THC-COOH were baseline-resolved using a PFP-type column with formic-acidified water (A) / methanol (B) mobile phases and an optimized gradient; high-resolution MS supported confident identification.
• Stability: THC and metabolites are matrix- and container-sensitive. Poor stability was noted for urine in polyethylene tubes stored at room temperature; blood concentrations fell over weeks at room temperature depending on tube type. Freezing at −20°C in sodium heparin (green-top) tubes improved stability to 6–12 months per literature.

Practical benefits and applications

Incorporating THC into a consolidated LC-MS toxicology panel offers:

• Operational efficiency by avoiding separate THC-specific assays and duplicate extractions.
• Cost and time savings in high-throughput forensic and clinical laboratories.
• Improved forensic value through simultaneous detection of recent-use markers (THC, 11-OH-THC) in blood/oral fluid and long-window urine markers (THC-COOH, glucuronide).
• Robust, defensible data for impaired-driving, medicolegal death and workplace testing when chromatographic selectivity, appropriate cutoffs and careful sample handling are implemented.

Future trends and applications

Anticipated directions and opportunities:

• Broader adoption of mixed-mode SPE and optimized organic content in workflows for lipophilic analytes to reduce adsorption-related losses.
• Increased use of high-resolution accurate-mass instruments for definitive confirmation of isomers and metabolites in complex matrices.
• Standardization of collection devices and buffers optimized for THC stability (e.g., Quantisal or similar) to harmonize results across laboratories.
• Further method integration to include new synthetic cannabinoids and emerging cannabis-related analytes into multi-class panels with validated cutoffs by matrix.
• Development of validated stability protocols and container recommendations to support long-term forensic storage and retrospective testing.

Conclusion

THC and its metabolites can be successfully integrated into broad LC-MS toxicology panels if method developers address three key areas: minimize lipophilic analyte loss by controlling organic content and consumable chemistry, choose chromatographic phases suited for THC and isomer separation (biphenyl or PFP rather than relying solely on C18), and validate extraction, elution and dry-down steps with recovery and stability experiments. Implemented correctly, these measures yield high recovery, improved sensitivity and reliable detection across oral fluid, blood and urine for forensic applications.

Reference

1. National Transportation Safety Board. Alcohol, Other Drug, and Multiple Drug Use Among Drivers. Safety study (2022).
2. Center for Behavioral Health Statistics. Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. (2024).
3. Watanabe K., Yamaori S., Funahashi T., Kimura T., Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannibols and cannabinol by human hepatic microsomes. Life Sci. 2007;80(15):1415-1419. doi:10.1016/j.lfs.2006.12.032
4. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, Δ9-tetrahydrocannabinol, cannabidiol and cannabinol. Handbook of Experimental Pharmacology. 2005;168:657-690. doi:10.1007/3-540-26573-2_23
5. Patterson C., Hassell K. Thermo Fisher Scientific Technical Note 003851. Quantitation of an oral fluid drug panel including THC using the new Stellar mass spectrometer.
6. Djilali E., Pappalardo L., Posadino AM., Giordo R., Pintus G. Effects of the storage conditions on the stability of natural and synthetic cannabis in biological matrices for forensic toxicology analysis: An update from the literature. Metabolites. 2022;12(9):801. doi:10.3390/metabo12090801